SARS-CoV-2

As scientific conferences return to in person programming, we still need COVID-19 precautions.

What do zoonotic spillover events reveal about virus-host biology and how do scientists use these lessons to inform future mitigation strategies? 

Researchers investigate new approaches to revolutionizing vaccines for cancer and infectious diseases. 

In the 21^st century, viral spillovers will become more and more common. We are not in the dark and can prepare now for new breakouts before they even begin.

It’s human nature to compare one’s success to others, but thinking that the grass is greener on the other side can be detrimental to one’s health. Recognizing strategies as equal but unique ways to tackle a common problem is a healthier perspective.

Learn how scientists detect viral pathogens lurking in the environment to mitigate infectious disease threats. 

LIVE April 19th, 2022 at 11:30 AM
Biologics targeting coronavirus and variants of interest emerge as the latest therapeutic strategy for treating COVID-19.

LIVE November 29th, 2021 at 11:00 AM ET
Investigating the pathophysiology and spread of human viruses

Vaccine development for infectious diseases gives rise to new vaccine approaches and accelerated development and approval timelines.

A naturally occurring nanoparticle yields a new type of vaccine that offers broad-acting protection against emerging SARS-CoV-2 variants. With further development, the approach may lead to a pan-coronavirus vaccine.